Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06430580 · ClinicalTrials.gov registry record · Early Phase 1
Cannabinoids and Biological Reactivity to Stress
A Early Phase 1 study of Cannabis Use Disorder, sponsored by Florida State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06430580: Recruiting Early Phase 1 study of Cannabis Use Disorder, sponsored by Florida State University.
NCT06430580 is a Early Phase 1 study of Cannabis Use Disorder that is actively recruiting participants, run by Florida State University. The registered enrollment target is 36 participants, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06430580, a Early Phase 1 study of Cannabis Use Disorder, is actively recruiting participants, sponsored by Florida State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test the impact of two drugs that produce temporary stress-like symptoms, both in isolation and together, on cannabis use motivation in individuals with Cannabis Use Disorder. The main questions it will answer are: 1. How do different forms of stress affect cannabis use motivation? 2. How do different forms of stress affect the body's natural cannabinoids? Researchers will compare a placebo to both drugs in isolation, as well as together, across four separate lab visits. Participants will: 1\) Complete a clinical screening interview (by phone or in-person) and visit the lab for a medical screening, and if eligible: a) Visit the lab four times where they will: i). Take one of four drug combinations ii). Complete an interview, questionnaires, and computerized tasks iii). Have their brain activity recorded with an EEG cap iv). Provide three blood samples
Primary Outcome
Change in electroencephalography-recorded (EEG) late positive potential amplitude to cannabis cue images after hydrocortisone (with or without yohimbine) compared to placebo+placebo and yohimbine+placebo conditions (higher amplitudes indicate worse outcome)
Conditions Studied
Interventions
- DRUG Hydrocortisone Oral
- DRUG Yohimbine Hydrochloride
- DRUG Cornstarch Placebo 20mg
- DRUG Cornstarch Placebo 54mg
Study Locations (1)
Florida
- The BRAINS Lab at Florida State University - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-09-30 |
| Phase | Early Phase 1 |
What NCT06430580 shows while recruiting
NCT06430580 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Hydrocortisone Oral is the first listed.
NCT06430580 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06430580 about?
NCT06430580 is a clinical study titled "Cannabinoids and Biological Reactivity to Stress". The goal of this study is to test the impact of two drugs that produce temporary stress-like symptoms, both in isolation and together, on cannabis use motivation in individuals with Cannabis Use Disorder. The main questions it will answer are: 1. How do different forms of stress affect cannabis use...
What is the current status of trial NCT06430580?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2024-09-30. Estimated completion is 2026-09-30.
What conditions does trial NCT06430580 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT06430580?
The interventions under investigation include: Hydrocortisone Oral (DRUG), Yohimbine Hydrochloride (DRUG), Cornstarch Placebo 20mg (DRUG), Cornstarch Placebo 54mg (DRUG).
Who is sponsoring clinical trial NCT06430580?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06430580 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06430580's enrollment target sits among peer trials
36 27th of 34 higher than 8 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
Progesterone for Cannabis Withdrawal
COMPLETED · Early Phase 1
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
RECRUITING · NA
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
Psilocybin-assisted Treatment for Cannabis Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI